Skip to Main Content

Cancer: Overview of Types, Symptoms, & Treatments: Leukemia

A research topic guide cover aspects of cancer.

Reference

Online Resources

Streaming Media

Perspectives

Between Two Kingdoms

NEW YORK TIMES BESTSELLER * A deeply moving memoir of illness and recovery that traces one young woman's journey from diagnosis to remission to re-entry into "normal" life--from the founder of The Isolation Journals and a subject of the Netflix documentary American Symphony ONE OF THE BEST BOOKS OF THE YEAR: The New York Times Book Review, The Washington Post, Bloomberg, The Rumpus, She Reads, Library Journal, Booklist "I was immersed for the whole ride and would follow Jaouad anywhere. . . . Her writing restores the moon, lights the way as we learn to endure the unknown."--Chanel Miller, The New York Times Book Review   "Beautifully crafted . . . affecting . . . a transformative read . . . Jaouad's insights about the self, connectedness, uncertainty and time speak to all of us."--The Washington Post In the summer after graduating from college, Suleika Jaouad was preparing, as they say in commencement speeches, to enter "the real world." She had fallen in love and moved to Paris to pursue her dream of becoming a war correspondent. The real world she found, however, would take her into a very different kind of conflict zone. It started with an itch--first on her feet, then up her legs, like a thousand invisible mosquito bites. Next came the exhaustion, and the six-hour naps that only deepened her fatigue. Then a trip to the doctor and, a few weeks shy of her twenty-third birthday, a diagnosis: leukemia, with a 35 percent chance of survival. Just like that, the life she had imagined for herself had gone up in flames. By the time Jaouad flew home to New York, she had lost her job, her apartment, and her independence. She would spend much of the next four years in a hospital bed, fighting for her life and chronicling the saga in a column for The New York Times. When Jaouad finally walked out of the cancer ward--after countless rounds of chemo, a clinical trial, and a bone marrow transplant--she was, according to the doctors, cured. But as she would soon learn, a cure is not where the work of healing ends; it's where it begins. She had spent the past 1,500 days in desperate pursuit of one goal--to survive. And now that she'd done so, she realized that she had no idea how to live. How would she reenter the world and live again? How could she reclaim what had been lost? Jaouad embarked--with her new best friend, Oscar, a scruffy terrier mutt--on a 100-day, 15,000-mile road trip across the country. She set out to meet some of the strangers who had written to her during her years in the hospital: a teenage girl in Florida also recovering from cancer; a teacher in California grieving the death of her son; a death-row inmate in Texas who'd spent his own years confined to a room. What she learned on this trip is that the divide between sick and well is porous, that the vast majority of us will travel back and forth between these realms throughout our lives. Between Two Kingdoms is a profound chronicle of survivorship and a fierce, tender, and inspiring exploration of what it means to begin again.

Adult Acute Lymphocytic Leukemia

The current explosion of new areas of controversy in the treatment of acute lymphocytic leukemia in adults and young adults makes this comprehensive book a much needed reference for hematologists and oncologists. This book assembles leading authorities from around the globe to cover the full spectrum of ALL subtypes and their treatments. Specific topics of discussion include indications for allogeneic bone marrow transplant in first complete remission, the role of minimal residual disease in making treatment decisions, the treatment of young adults, and the treatment of Philadelphia chromosome positive ALL with the advent of the tyrosine kinase inhibitors. This is the first book to focus exclusively on the adult ALL patient. It provides a complete overview of diagnosis, molecular pathogenesis, evaluation, and treatment for this important patient population.

The Philadelphia Chromosome

A Wall Street Journal 10 Best Nonfiction Book of the Year "Among a small cluster of very good recent books on cancer." --The New York Times Philadelphia, 1959: A scientist scrutinizing a single human cell under a microscope detects a missing piece of DNA. That scientist, David Hungerford, had no way of knowing that he had stumbled upon the starting point of modern cancer research-- the Philadelphia chromosome. It would take doctors and researchers around the world more than three decades to unravel the implications of this landmark discovery. In 1990, the Philadelphia chromosome was recognized as the sole cause of a deadly blood cancer, chronic myeloid leukemia, or CML. Cancer research would never be the same. Science journalist Jessica Wapner reconstructs more than forty years of crucial breakthroughs, clearly explains the science behind them, and pays tribute--with extensive original reporting, including more than thirty-five interviews--to the dozens of researchers, doctors, and patients with a direct role in this inspirational story. Their curiosity and determination would ultimately lead to a lifesaving treatment unlike anything before it. The Philadelphia Chromosome chronicles the remarkable change of fortune for the more than 70,000 people worldwide who are diagnosed with CML each year. It is a celebration of a rare triumph in the battle against cancer and a blueprint for future research, as doctors and scientists race to uncover and treat the genetic roots of a wide range of cancers.

Childhood Leukemia

This book is a comprehensive and up-to-date compendium on all aspects of childhood leukemia. After introductory chapters on the epidemiology and biology of pediatric leukemia, treatment considerations are extensively reviewed, with emphasis on the use of risk-adjusted treatment approaches. Promising targeted agents are discussed, and strategies for the development of new agents are appraised. The late effects of leukemia and its therapy are then considered in depth, with due attention to management of the psychosocial impact of the disease. Finally, global strategies to improve leukemia care and outcome are reviewed, and future directions discussed. The authors are internationally recognized experts and offer a largely evidence-based consensus on etiology, biology, and treatment. This handbook has far-reaching applicability to the clinical diagnosis and management of pediatric leukemia and will prove invaluable to specialists, generalists, and trainees alike.

Human T-Cell Leukemia Virus

characteristic features in common with the genome of other retroviruses: long terminal repeats (L TR), and coding regions for internal proteins (gag), for re­ verse transcriptase (pol), and for glycosylated virion surface proteins (env) , ar­ ranged in the sequence gag, pol, env from the 5' to the 3' end of the genome. However, the HTL V genome also contains some specific features not shared with all other retroviruses: the LTR regions are unusually long (745 base pairs, with 298 base pairs constituting the R region), but unlike the long L TRs of mouse mammary tumor viruses, they do not contain open reading frames. A stretch of noncoding sequences separates the gag and the pol genes. Most interestingly, the HTLV genome contains a region between the 3' end of the env gene and the L TR, called the pX region, that encompasses four open reading frames. Leukemic T cells freshly obtained from patients contain the HTL V provirus but usually do not express it. However, once established in culture, these cells produce viral proteins and release type C particles. Likewise, T cells infected and transformed by HTL V in vitro synthesize virus. Such producing cell lines have been widely used in seroepidemiological surveys and continue to be of importance for detailed studies of viral proteins and nucleic acids.